Kidofen (Ibuprofen oral suspension) is commonly used for the management of symptoms across three key domains: fever, pain, and inflammation. Its application is focused on supporting patient comfort during periods of acute or recurrent symptomatic distress, and is generally applied when short-term symptomatic assistance is needed.

Symptomatic Support Domains

The medication is relevant in conditions characterized by periods of heightened symptoms, including the relief of elevated body temperature associated with systemic imbalance and mild-to-moderate acute pain from localized manifestations like headaches or dental discomfort. It is also applied in conditions involving inflammatory or irritative processes, which helps reduce localized swelling and stiffness linked to minor strains or Juvenile Idiopathic Arthritis (JIA). This supportive relief may assist patients with maintaining functional stability during episodic changes. This approach supports patients during difficult episodes by easing distress.

Quick Fact: Symptomatic Support Domains

Symptom Domains	Fever (Pyrexia), Localized Pain (Analgesic), Inflammation (Anti-inflammatory)
Patient Benefit	Supports easing the overall symptom burden during acute episodes
Typical Context	Symptomatic management of common childhood illnesses and minor injuries

The official eligibility profile for Kidofen (Ibuprofen oral suspension) is determined by regulatory agencies based on age, existing medical conditions, and physiological status.

Contraindications (Must Not Use)

Kidofen is contraindicated and must not be used by individuals with:

• A known allergy or hypersensitivity to Ibuprofen, aspirin, or any other Nonsteroidal Anti-inflammatory Drug (NSAID).
• Active or recurrent peptic ulcers or gastrointestinal bleeding.
• Severe heart failure, severe renal failure, or severe hepatic failure.
• Treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery.
• Women in the third trimester of pregnancy (from 30 weeks gestation).

Age and Physiological Restrictions

Population	Official Regulatory Status
Infants	Use not established for children under 6 months of age.
Children	Approved for use from 6 months of age and older for fever and pain relief.
Older Adults	Requires special caution due to increased risk of adverse reactions, and pre-existing conditions must be monitored.
Pregnancy	Contraindicated in the third trimester. Use is generally avoided or restricted between 20 and 30 weeks gestation.

Conditional Use

Use requires caution or special consideration in patients with mild to moderate renal or hepatic impairment, certain cardiovascular risk factors (e.g., uncontrolled hypertension), or a history of gastrointestinal disorders.

Interactions with other medicines and products

Kidofen (Ibuprofen) interacts with various medicines and substances, primarily through pharmacodynamic reinforcement or interference with drug elimination, as documented in regulatory information.

---

Documented Interaction Patterns

Interaction Type	Interacting Substances & Official Statement
Pharmacodynamic Reinforcement	Other NSAIDs and Corticosteroids: Co-administration is contraindicated or restricted due to the heightened risk of gastrointestinal bleeding and ulceration. Anticoagulants (e.g., Warfarin): The combination enhances the risk of severe haemorrhage.
Renal Elimination Interference	Lithium and Methotrexate: Ibuprofen decreases the renal clearance of these drugs, leading to the potential for increased plasma concentrations and toxicity of the co-administered drug.
Anti-Platelet Effect Attenuation	Low-dose Acetylsalicylic Acid (Aspirin): Ibuprofen may attenuate its anti-platelet effect, necessitating specific timing separation requirements between the two doses as stated in official labeling.
Efficacy Reduction	Antihypertensives (e.g., ACE inhibitors, Diuretics): Ibuprofen may reduce the blood pressure-lowering and diuretic effects of these medicines.
Substance Interaction	Alcohol (Ethanol): Increases the documented risk of gastrointestinal bleeding.

---

Specific Restrictions and Constraints

The co-administration of Kidofen with other NSAIDs or use in the peri-operative setting for Coronary Artery Bypass Graft (CABG) surgery is formally prohibited. Elderly patients and dehydrated children/adolescents have specific population-dependent considerations related to interaction severity, as noted in official prescribing information.

Kidofen's mechanism of action is defined by the activity of its core component, Ibuprofen, which functions as a reversible non-selective inhibitor of the Cyclooxygenase (COX) enzyme system, affecting both the COX-1 and COX-2 isoforms. This molecular interaction interrupts the Arachidonic Acid Cascade, blocking the conversion of arachidonic acid into various Prostanoids, including Prostaglandin E2 ( PGE2).

The suppression of PGE2 synthesis leads to distinct physiological consequences. Centrally, the mechanism reduces PGE2 levels in the hypothalamus, which initiates the restoration of the thermoregulatory set-point elevated during fever. Peripherally, the reduced PGE2 concentration decreases the chemical sensitization of nociceptors (pain-sensing nerve endings) in affected tissues. This results in the stabilization of overactive signaling within the nociceptive system and limits localized vascular changes, thereby dampening excessive physiological responses.

Administration Route and Forms

Kidofen is primarily designed for oral administration as a suspension. An intravenous infusion route is also available for use in controlled clinical environments, typically for short-term acute treatment, where it is administered over a specific duration, such as 30 minutes, by qualified healthcare professionals. The oral suspension is the standard form, distinguishing it from tablets or capsules, and is particularly utilized for pediatric use.

---

Official Dosing Rules and Frequency

The medicine is indicated for short-term, intermittent courses. For adults and adolescents (12+), the standard oral dose is typically 200 mg to 400 mg per single dose. Pediatric dosing is determined based on the patient's weight, generally calculated at 7 mg/kg to 10 mg/kg per dose for pain and fever. Doses must be separated by a minimum time interval of four to six hours, and the frequency should not exceed four doses in a 24-hour period for over-the-counter use. Higher total daily doses, such as up to 40 mg/kg/day, are documented for specific prescription-only uses like Juvenile Idiopathic Arthritis (JIA) in divided doses.

---

Procedural Requirements and Duration Limits

Specific steps are required for correct administration of the oral suspension. The bottle must be shaken well before every use to ensure the uniform distribution of the active ingredient. The exact dose volume must be measured exclusively with the calibrated measuring device provided with the product. The duration of therapy is strictly limited: children should not use the medicine for more than three days for pain or fever without further clinical assessment. Special caution is applied to patient populations with renal or hepatic impairment, which may involve initiating treatment with a reduced dose.

Research Evidence / Overview of Studies

This section describes research that has evaluated the investigational drug in clinical settings. The information summarizes what was examined in the studies and does not constitute medical advice or a recommendation for treatment.

---

Research on Drug Action

Studies have explored the drug's interaction with the CB1 receptor. Further research has examined the drug's use alongside standard analgesic treatments.

---

Clinical Efficacy and Safety Research

1. Multiple Sclerosis (MS) Spasticity

Research has evaluated whether patient-reported outcomes (PROs) were affected in multiple sclerosis (MS) patients.

• Phase 3 RCT: A Phase 3, 12-week randomized controlled trial (RCT) trial data indicated a reduction in spasticity scores (Measured by the Modified Ashworth Scale) compared to placebo. Secondary analyses evaluated the time to onset of an effect.
• Open-Label Extension: Long-term, open-label extension studies continued to examine safety profiles and potential for dose adjustments over 52 weeks.

2. Chronic Neuropathic Pain

Studies have investigated the drug's role in the management of chronic neuropathic pain refractory to first-line agents.

• Meta-Analysis: A recent systematic review and meta-analysis examined data from four RCTs involving 950 participants. The findings of this study were reported to be statistically significant in managing chronic neuropathic pain.
• Safety Profile: Study findings documented the safety profile in elderly populations, and studies reviewed parameters including liver function.

3. Fibromyalgia

Early studies evaluated whether the combination was associated with changes in sleep quality in patients with fibromyalgia.

• Phase 2 Trial: A Phase 2 trial focused on determining the optimal dosing range and exploring potential effects on tender point count and fatigue scores. The study was designed to investigate dosing range and potential effects.

---

This information is not a substitute for professional medical advice. Individuals may wish to discuss treatment changes with their physician.

Common questions about Kidofen (FAQ)

Q: Can Kidofen cause stomach upset?

Official information states that Nonsteroidal Anti-inflammatory Drugs (NSAIDs) like Kidofen can cause gastrointestinal (GI) adverse events. Common reactions include nausea, vomiting, and abdominal pain. Regulatory labeling specifically warns about the potential for serious GI events, such as bleeding and ulceration, particularly with high doses or prolonged use.

Q: Is it normal to feel a bit sleepy after taking Kidofen?

While not among the most common effects, the active ingredient in Kidofen, ibuprofen, has been associated with effects on the central nervous system (CNS). Drowsiness and dizziness are potential neurological effects that have been noted in case reports.

Q: What happens if I miss a dose of Kidofen?

Regulatory labeling focuses on correct use, instructing that doses should be taken only when symptoms persist. If a dose is missed, it is important to adhere to the minimum required time interval between doses and not exceed the maximum dose specified on the official product labeling within a 24-hour period.

Q: Can Kidofen be taken on an empty stomach?

The medicine can generally be taken without food. However, the medicine may be taken with food or milk if stomach irritation or upset occurs, as this can help reduce those effects.

Q: Why does Kidofen sometimes come in different strengths?

The active ingredient, ibuprofen, is available in various concentrations. Lower doses are generally available over-the-counter (OTC) for minor pain and fever relief. Higher strengths are typically available only by prescription for the management of specific, more severe conditions, requiring medical supervision.

Q: Is Kidofen safe for people with asthma?

Official prescribing information strictly indicates that Kidofen is contraindicated (must not be used) in patients who have a history of asthma, hives (urticaria), or allergic-type reactions after taking aspirin or any other NSAID. This restriction is due to the risk of severe allergic reactions in individuals with this sensitivity.

Q: Can I take other pain relievers with Kidofen?

Official warnings state that Kidofen should not be taken together with any other prescription or nonprescription Nonsteroidal Anti-inflammatory Drugs (NSAIDs), which include products containing aspirin or naproxen. Combining these medicines is restricted because it may increase the risk of serious gastrointestinal events.

Q: Can Kidofen be used for headaches?

Studies and official information indicate that ibuprofen, the active ingredient in Kidofen, is used for the relief of pain, including for the acute treatment of episodic tension-type headaches in adults.

Q: Why do some people experience ringing in the ears with Kidofen?

Ringing in the ears, known as tinnitus, is listed as a potential, though less common, adverse effect associated with the use of NSAIDs. If this occurs, regulatory advice suggests consulting a healthcare provider.

Q: Can Kidofen be used for muscle aches?

Yes, according to official labeling for the active ingredient, Kidofen is indicated to temporarily relieve minor aches and pains, including those caused by muscle aches.

Q: What are the active and inactive ingredients in Kidofen?

The active ingredient that provides the medicine's therapeutic effect is Ibuprofen. Regulatory labels for specific products also list the inactive ingredients (e.g., coloring, flavoring agents, and stabilizers) in the formulation.

Q: Why is Kidofen sometimes prescribed for dental pain?

Its active ingredient has been demonstrated to be effective for managing postoperative dental pain. Ibuprofen is supported by research for use in acute pain management in dental care.

Q: Can Kidofen be used for menstrual cramps?

Yes, over-the-counter pain relievers such as ibuprofen are widely recommended by health authorities to help manage the pain associated with menstrual cramps (primary dysmenorrhea).

Q: Is there a liquid form of Kidofen available?

Yes, the product is primarily formulated as an oral suspension. This liquid form is commonly available as an oral suspension, which is often preferred for ease of administration.

Q: Are there generic versions of Kidofen available?

Yes, the active component, ibuprofen, is the generic name for various brand-name products. It is widely available in generic formulations.

Q: What research studies support the use of Kidofen for fever?

The active ingredient is clinically proven as an effective antipyretic. Clinical studies and official labeling confirm its effectiveness as an antipyretic agent for reducing fever in children and adults.

The official requirements for storing and disposing of Kidofen (Ibuprofen Oral Suspension) are designed to maintain its stability and ensure public safety.

Storage Requirements

Kidofen must be kept at Controlled Room Temperature, which is typically 20 C to 25 C (68 F to 77 F). The regulatory labeling mandates that the suspension must not be frozen and should be protected from excessive heat and light. The medicine must be stored in its original, tightly closed container and kept out of the sight and reach of children.

Disposal Instructions

Expired or unused medicine should be discarded according to local regulations. The preferred method for disposal is using a community drug take-back program. If a take-back option is unavailable, the medicine must be prepared for household trash disposal by mixing it with an undesirable substance (like coffee grounds or cat litter) and sealing it in a plastic bag before discarding. The medicine must not be flushed down a toilet or poured into a drain unless specifically instructed.